Investors Purchase Large Volume of Call Options on Recursion Pharmaceuticals (NASDAQ:RXRX)

Posted by Francis Steltz on Sep 19th, 2026

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) was the recipient of some unusual options trading activity on Thursday. Traders purchased 25,291 call options on the company. This represents an increase of 50% compared to the average daily volume of 16,872 call options.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on RXRX. Wall Street Zen raised Recursion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Saturday, August 29th. Morgan Stanley set a $5.30 price target on Recursion Pharmaceuticals in a research note on Monday, August 17th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a report on Friday, July 17th. Two research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $8.06.

Get Our Latest Report on Recursion Pharmaceuticals

Insider Buying and Selling at Recursion Pharmaceuticals

In other news, Director Blake Borgeson sold 30,000 shares of the company’s stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $3.34, for a total transaction of $100,200.00. Following the completion of the sale, the director owned 6,158,287 shares in the company, valued at approximately $20,568,678.58. This represents a 0.48% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Najat Khan sold 22,408 shares of the company’s stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $3.52, for a total transaction of $78,876.16. Following the sale, the chief executive officer directly owned 2,072,890 shares of the company’s stock, valued at approximately $7,296,572.80. This represents a 1.07% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 122,408 shares of company stock valued at $434,976. 6.65% of the stock is owned by company insiders.

Institutional Investors Weigh In On Recursion Pharmaceuticals

Institutional investors have recently made changes to their positions in the stock. Norges Bank bought a new position in shares of Recursion Pharmaceuticals in the 4th quarter worth about $23,473,000. Lingotto Investment Management LLP lifted its position in Recursion Pharmaceuticals by 34.2% in the 4th quarter. Lingotto Investment Management LLP now owns 4,931,057 shares of the company’s stock valued at $20,168,000 after acquiring an additional 1,255,980 shares in the last quarter. First Trust Advisors LP grew its stake in shares of Recursion Pharmaceuticals by 15.2% in the 1st quarter. First Trust Advisors LP now owns 2,610,726 shares of the company’s stock worth $8,015,000 after acquiring an additional 344,035 shares in the last quarter. Bank of America Corp DE lifted its position in shares of Recursion Pharmaceuticals by 18.2% during the first quarter. Bank of America Corp DE now owns 2,496,831 shares of the company’s stock valued at $7,665,000 after purchasing an additional 384,486 shares in the last quarter. Finally, Renaissance Technologies LLC bought a new position in shares of Recursion Pharmaceuticals in the first quarter valued at approximately $7,370,000. Institutional investors own 89.06% of the company’s stock.

Recursion Pharmaceuticals Stock Up 8.2%

Shares of RXRX opened at $3.83 on Friday. The firm has a market cap of $2.05 billion, a P/E ratio of -3.68 and a beta of 1.07. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.03 and a current ratio of 5.03. Recursion Pharmaceuticals has a 52 week low of $2.77 and a 52 week high of $7.18. The firm’s 50-day simple moving average is $3.26 and its 200 day simple moving average is $3.32.

Recursion Pharmaceuticals (NASDAQ:RXRX – Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.01). Recursion Pharmaceuticals had a negative return on equity of 50.41% and a negative net margin of 945.94%.The business had revenue of $7.67 million during the quarter, compared to analyst estimates of $10.97 million. During the same quarter last year, the firm earned ($0.41) EPS. On average, analysts forecast that Recursion Pharmaceuticals will post -0.92 earnings per share for the current year.

Recursion Pharmaceuticals Company Profile

(Get Free Report)

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biotechnology company that uses artificial intelligence, automation, and large-scale biological experimentation to accelerate the discovery and development of medicines. Its technology platform, known as the Recursion Operating System, integrates data from biology, chemistry, imaging, and machine learning to identify potential drug candidates and better understand disease biology.

The company develops therapies for areas including oncology, rare diseases, and neurological disorders.